

Meehyein Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3760828/publications.pdf>

Version: 2024-02-01

56
papers

1,593
citations

361413

20
h-index

302126

39
g-index

59
all docs

59
docs citations

59
times ranked

2807
citing authors

#	ARTICLE	IF	CITATIONS
1	Generation of human tonsil epithelial organoids as an ex vivo model for SARS-CoV-2 infection. <i>Biomaterials</i> , 2022, 283, 121460.	11.4	14
2	The efficacy of a 2,4-diaminoquinazoline compound as an intranasal vaccine adjuvant to protect against influenza A virus infection in vivo. <i>Journal of Microbiology</i> , 2022, 60, 550-559.	2.8	3
3	Determination of the vRNA and cRNA promoter activity by M segment-specific non-coding nucleotides of influenza A virus. <i>RNA Biology</i> , 2021, 18, 785-795.	3.1	1
4	Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2. <i>Scientific Reports</i> , 2021, 11, 821.	3.3	70
5	Sulfamoylbenzamide-based Capsid Assembly Modulators for Selective Inhibition of Hepatitis B Viral Replication. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 242-248.	2.8	11
6	Comparison of Antiviral Activity of Gemcitabine with 2-Fluoro-2-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1581.	4.1	18
7	Antiviral Activity of Isoquinolone Derivatives against Influenza Viruses and Their Cytotoxicity. <i>Pharmaceuticals</i> , 2021, 14, 650.	3.8	5
8	Electrochemical Synthesis of 3D Plasmonic-Molecule Nanocomposite Materials for In Situ Label-Free Molecular Detections. <i>Advanced Materials Interfaces</i> , 2021, 8, 2101201.	3.7	2
9	Current Progress in the Development of Hepatitis B Virus Capsid Assembly Modulators: Chemical Structure, Mode-of-Action and Efficacy. <i>Molecules</i> , 2021, 26, 7420.	3.8	20
10	Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment. <i>European Journal of Medicinal Chemistry</i> , 2020, 188, 112031.	5.5	9
11	Structural and biophysical properties of RIG-I bound to dsRNA with G-U wobble base pairs. <i>RNA Biology</i> , 2020, 17, 325-334.	3.1	0
12	SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115679.	3.0	3
13	TRIM Proteins and Their Roles in the Influenza Virus Life Cycle. <i>Microorganisms</i> , 2020, 8, 1424.	3.6	10
14	In Vitro and In Vivo Antiviral Activity of Nylidrin by Targeting the Hemagglutinin 2-Mediated Membrane Fusion of Influenza A Virus. <i>Viruses</i> , 2020, 12, 581.	3.3	10
15	Discrimination between target and non-target interactions on the viral surface by merging fluorescence emission into Rayleigh scattering. <i>Nanoscale</i> , 2020, 12, 7563-7571.	5.6	4
16	Brain Cytoplasmic RNAs in Neurons: From Biosynthesis to Function. <i>Biomolecules</i> , 2020, 10, 313.	4.0	4
17	Antiviral activity of sertindole, raloxifene and ibutamoren against transcription and replication-competent Ebola virus-like particles. <i>BMB Reports</i> , 2020, 53, 166-171.	2.4	12
18	Neutralization of Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple Steps of the Dengue Virus Life Cycle In Vitro. <i>Scientific Reports</i> , 2019, 9, 8682.	3.3	23

#	ARTICLE	IF	CITATIONS
19	Development of a Subtype-Specific Diagnostic System for Influenza Virus H3N2 Using a Novel Virus-Based Systematic Evolution of Ligands by Exponential Enrichment (Viro-SELEX). <i>Journal of Biomedical Nanotechnology</i> , 2019, 15, 1609-1621.	1.1	13
20	Heterogeneous Sequences of Brain Cytoplasmic 200 RNA Formed by Multiple Adenine Nucleotide Insertions. <i>Molecules and Cells</i> , 2019, 42, 495-500.	2.6	0
21	Heterogeneous Sequences of Brain Cytoplasmic 200 RNA Formed by Multiple Adenine Nucleotide Insertions. <i>Molecules and Cells</i> , 2019, 42, 495-500.	2.6	1
22	Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. <i>Nucleic Acids Research</i> , 2018, 46, 1635-1647.	14.5	7
23	Salinomycin Inhibits Influenza Virus Infection by Disrupting Endosomal Acidification and Viral Matrix Protein 2 Function. <i>Journal of Virology</i> , 2018, 92, .	3.4	50
24	Systematic editing of synthetic RIG-I ligands to produce effective antiviral and anti-tumor RNA immunotherapies. <i>Nucleic Acids Research</i> , 2018, 46, 10533-10533.	14.5	3
25	Identification of quinone analogues as potential inhibitors of picornavirus 3C protease in vitro. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 2533-2538.	2.2	11
26	Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro. <i>Viruses</i> , 2018, 10, 283.	3.3	69
27	BC200 RNA: An Emerging Therapeutic Target and Diagnostic Marker for Human Cancer. <i>Molecules and Cells</i> , 2018, 41, 993-999.	2.6	18
28	Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CL Pro inhibitors. <i>Antiviral Research</i> , 2017, 141, 101-106.	4.1	77
29	CRISPR/Cas9-mediated gene knockout screens and target identification via whole-genome sequencing uncover host genes required for picornavirus infection. <i>Journal of Biological Chemistry</i> , 2017, 292, 10664-10671.	3.4	33
30	Evaluation and Clinical Validation of Two Field-Deployable Reverse Transcription-Insulated Isothermal PCR Assays for the Detection of the Middle East Respiratory Syndrome-Coronavirus. <i>Journal of Molecular Diagnostics</i> , 2017, 19, 817-827.	2.8	35
31	Comparison of anti-influenza virus activity and pharmacokinetics of oseltamivir free base and oseltamivir phosphate. <i>Journal of Microbiology</i> , 2017, 55, 979-983.	2.8	11
32	Characterization and mechanisms of anti-influenza virus metabolites isolated from the Vietnamese medicinal plant <i>Polygonum chinense</i> . <i>BMC Complementary and Alternative Medicine</i> , 2017, 17, 162.	3.7	41
33	Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins. <i>Antiviral Research</i> , 2016, 134, 77-88.	4.1	14
34	Antiviral activity of micafungin against enterovirus 71. <i>Virology Journal</i> , 2016, 13, 99.	3.4	30
35	Synergistic antiviral activity of gemcitabine and ribavirin against enteroviruses. <i>Antiviral Research</i> , 2015, 124, 1-10.	4.1	59
36	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 9546-9561.	6.4	16

#	ARTICLE	IF	CITATIONS
37	Synthesis and anti-influenza virus activity of 4-oxo- or thioxo-4,5-dihydrofuro[3,4-c]pyridin-3(1H)-ones. <i>Antiviral Research</i> , 2014, 107, 66-75.	4.1	17
38	A novel small-molecule binds to the influenza A virus RNA promoter and inhibits viral replication. <i>Chemical Communications</i> , 2014, 50, 368-370.	4.1	58
39	Biophysical characterization of sites of host adaptive mutation in the influenza A virus RNA polymerase PB2 RNA-binding domain. <i>International Journal of Biochemistry and Cell Biology</i> , 2014, 53, 237-245.	2.8	4
40	Efficient synthesis of 3 H ,3â€² H -spiro[benzofuran-2,1â€²-isobenzofuran]-3,3â€²-dione as novel skeletons specifically for influenza virus type B inhibition. <i>European Journal of Medicinal Chemistry</i> , 2013, 62, 534-544.	5.5	50
41	Inhibition of influenza virus internalization by (âˆ™)-epigallocatechin-3-gallate. <i>Antiviral Research</i> , 2013, 100, 460-472.	4.1	108
42	Branched, Tripartite-Interfering RNAs Silence Multiple Target Genes with Long Guide Strands. <i>Nucleic Acid Therapeutics</i> , 2012, 22, 30-39.	3.6	20
43	Aminoglycoside antibiotics bind to the influenza A virus RNA promoter. <i>Molecular BioSystems</i> , 2012, 8, 2857.	2.9	16
44	In vitro inhibition of influenza A virus infection by marine microalga-derived sulfated polysaccharide p-KG03. <i>Antiviral Research</i> , 2012, 93, 253-259.	4.1	143
45	Membrane-based hybridization capture of intracellular peptide nucleic acid. <i>Analytical Biochemistry</i> , 2010, 399, 135-137.	2.4	2
46	Optimization of linear double-stranded RNA for the production of multiple siRNAs targeting hepatitis C virus. <i>Rna</i> , 2009, 15, 898-910.	3.5	29
47	Hepatic siRNA delivery using recombinant human apolipoprotein A-I in mice. <i>Biochemical and Biophysical Research Communications</i> , 2009, 378, 192-196.	2.1	33
48	Targeted delivery of siRNA against hepatitis C virus by apolipoprotein A-I-bound cationic liposomes. <i>Journal of Hepatology</i> , 2009, 50, 479-488.	3.7	82
49	Systemic and Specific Delivery of Small Interfering RNAs to the Liver Mediated by Apolipoprotein A-I. <i>Molecular Therapy</i> , 2007, 15, 1145-1152.	8.2	159
50	Immunostimulatory properties and antiviral activity of modified HBV-specific siRNAs. <i>Biochemical and Biophysical Research Communications</i> , 2007, 364, 436-442.	2.1	21
51	Efficient inhibition of hepatitis B virus replication by small interfering RNAs targeted to the viral X gene in mice. <i>Virus Research</i> , 2006, 119, 146-153.	2.2	33
52	Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. <i>Virus Research</i> , 2006, 122, 1-10.	2.2	39
53	Structural requirements for assembly and homotypic interactions of the hepatitis C virus core protein. <i>Virus Research</i> , 2006, 122, 137-143.	2.2	11
54	Template Requirements for De Novo RNA Synthesis by Hepatitis C Virus Nonstructural Protein 5B Polymerase on the Viral X RNA. <i>Journal of Virology</i> , 2002, 76, 6944-6956.	3.4	37

#	ARTICLE	IF	CITATIONS
55	Effects of Terminal Deletions in C5 Protein on Promoting RNase P Catalysis. Biochemical and Biophysical Research Communications, 2000, 268, 118-123.	2.1	8
56	Effects of C5 Protein on Escherichia coli RNase P Catalysis with a Precursor tRNAPhe Bearing a Single Mismatch in the Acceptor Stem. Biochemical and Biophysical Research Communications, 2000, 268, 136-140.	2.1	12